Although 22q terminal deletions are well documented, very few patients with mosaicism have been reported. We describe two new cases with mosaic 22q13.2-qter deletion, detected by karyotype analysis, showing the neurological phenotype of 22q13.3 deletion syndrome. Case 1 represents an exceptional case of mosaicism for maternal 22q13.2-qter deletion (45% of cells) and 22q13.2-qter paternal segmental isodisomy (55% of cells). This complex situation was suspected because cytogenetic, FISH and array-CGH analyses showed the presence of an 8.8 Mb mosaic 22q13.2-qter deletion, whereas microsatellite marker analysis was consistent with maternal deletion without any evidence of mosaic deletion. Molecular analysis led to the definition of very close, but not coincident, deletion and uniparental disomy (UPD) break points. Furthermore, we demonstrated that the segmental UPD arose by gene conversion in the same region. In Case 2, mosaicism for a paternal 8.9 Mb 22q13.2-qter deletion (73% of cells) was detected. In both patients, the level of mosaicism was also verified in saliva samples. We propose possible causative mechanisms for both rearrangements. Although the size of the deletions was quite similar, the phenotype was more severe in Case 2 than in Case 1. As maternal UPD 22 has not been generally associated with any defects and as the size of the deletion is very similar in the two cases, phenotype severity is likely to depend entirely on the degree of mosaicism in each individual.
Introduction
To date, thanks to the increasing use of subtelomeric FISH tests, more than 100 cases with monosomy 22q13.3 have been reported. Among these, very few patients showed mosaicism for the 22q13.3 deletion; in fact, the majority of mosaic 22q13 deletions is the product of ring chromosome 22 or of a more complex structural chromosome 22 aberration involving a chromosome deletion and an inverted duplication combined with ring chromosome formation. 1 -6 We report two new cases of mosaicism for the del(22)(q13.2) diagnosed by routine conventional highresolution G-banded karyotype and refined by array CGH analysis. In one case, molecular characterization revealed additional mosaic segmental uniparental disomy (UPD) in the 'normal' cell line. Both patients showed all the main features of 22q13.3 deletion syndrome, suggesting that SHANK3 gene haploinsufficiency 7 -10 is sufficient to express the neurological phenotype of the syndrome even in mosaic.
Methods
Two patients with mosaic 22q13 deletion were ascertained through routine karyotype analysis. Clinical details are provided as Supplementary files. FISH experiments were performed with the ARSA probe (Vysis) and 22q-cosmid clones n66c4, n85a3, n94h12, and n1g3 as previously reported. 11 Array-based CGH was performed using the Agilent Human Genome CGH Microarray Kit 44B as previously described. 12 Genomic DNA was extracted from probands' blood, EBV cell lines, parents' blood, and saliva with standard protocols. Somatic cell hybrid clones were generated as in Giorda et al. 13 The UCSC Genome Browser (May 2004 assembly; http://genome.ucsc.edu/) maps and sequence were used as references. Genotyping of polymorphic sequence-tagged sites was performed by amplification with primers labeled with fluorescent probes followed by analysis on an ABI 310 Genetic Analyzer (Applied Biosystems). Amplifications were performed with AmpliTaq Gold (Applied Biosystems) using standard protocols.
Further genotyping was performed using the Illumina HumanHap500 single beadchip with 750 ng of genomic DNA at a standard concentration of 50 ng/ml. The process conformed to the manufacturer's protocols. The Illumina Beadstudio algorithm was used to call genotypes with manual analysis to confirm cluster boundaries.
Long-range PCRs were performed with JumpStart Red ACCUTaq LA DNA polymerase (Sigma). Fragments were cloned in pCR-4 TOPO using a TOPO TA cloning kit (Invitrogen). All sequencing reactions were performed with a Big Dye Terminator Cycle Sequencing kit (Applied Biosystems) and run on an ABI Prism 3130xl Genetic Analyzer.
For Case 1 break point cloning, two chromosome 22-specific primers adjacent to the deletion break points were designed and used for nested ACP-PCR. 11 PCR products were both directly sequenced and cloned, followed by sequencing of individual clones. Dilution cloning was performed by seeding 96-well plates with cells from Case 1 EBV line diluted to 0.3 cells per well in RPMI medium containing 10% FCS. DNA was extracted from the resulting clones with DNAzol.
Results

Clinical characteristics
Clinical features are summarized in Table 1 Array CGH analysis demonstrated that the deletion encompasses the terminal 8.8 Mb (Figure 1a ) and 8.9 Mb (Figure 1b) in Case 1 and in Case 2, respectively.
Typing of polymorphic chromosome 22 markers in the deleted interval in the probands and their parents demonstrated the following:
Case 1: the 22q13 deletion was of maternal origin without any evidence of mosaic deletion ( Figure 1c and Table 2 ).
Case 2: the 22q13 deletion involved the paternal chromosome 22, with evidence of deletion mosaicism (Figure 1d and Supplementary Table 1) .
Somatic cell hybrids, break point cloning, and sequencing As in Case 1 cytogenetic investigations had clearly demonstrated a mosaic 22q13.2-qter deletion, whereas microsatellite analysis showed a maternal deletion without any evidence of mosaicism, the presence of segmental paternal isodisomy in the 'normal' cell line was supposed. We tested this hypothesis on somatic cell hybrid clones made by fusing Case 1's lymphoblastoid line with a Hamster cell line.
We isolated and analyzed 76 clones with informative chromosome 22 markers. We found three clones with a normal paternal chromosome 22, one with a deleted maternal 22, one with a non-deleted maternal chromosome 22 with segmental paternal UPD of its distal portion ( Table 2) .
We mapped and cloned with ACP-PCR the break point of the deleted chromosome 22. The deletion break point is followed by a TT dinucleotide and a series of (AGGGTT) n telomeric repeats, and it localizes approximately in the middle of a 1.3 kb (GAAA) n (GAAAAA) n simple repeat in intron 5 of the CENPM gene ( (Table 2 ). These data demonstrate that deletion and segmental UPD break points, while very close, do not coincide. The deletion break point is located between chr22:40665726 and 40665857; the segmental (Figure 2a ). To find out how the different maternal and paternal chromosomes 22 were distributed in the mosaic lines, we obtained pure EBV subclones containing either the deleted or the UPD-22 chromosome by dilution cloning. We typed all subclones for SNPs 1030 -1050 and rs10483213, and for the telomere of the deleted chromosome 22. We found that the gene conversion carrying paternal chromosome 22 is associated with the maternal 22 with segmental UPD, while the paternal chromosome 22 that did not undergo gene conversion is associated with the deleted maternal 22 (Figure 2b and Supplementary Figure 2G -H) .
In addition to blood, we also analyzed EBV lines and saliva from each proband.
We found in Case 1 the same degree of mosaicism in the proband's blood (not shown), EBV line, and saliva (Supplementary Figure 2A and I) , whereas in Case 2 the level of mosaicism in different tissues seems to vary between 70 and 80% (Supplementary Figure 3) .
Discussion
Apart from patients with r(22) chromosomes, 14 -17 mosaicism for del(22)(q13) has so far been described in a 5.5-year-old girl with global developmental delay, epilepsy, and mild facial dysmorphisms, 18 and in two fetuses it was prenatally diagnosed because of ultrasound anomalies 19 and increased risk of Down's syndrome determined by maternal serum screening. 4 To the best of our knowledge, Case 1 represents the first patient with 22q13.3 deletion syndrome associated with a complex mosaic chromosome rearrangement consisting of a 22q13.2-qter chromosome deletion in 45% of her cells, and an apparently normal cell line that actually carries a 22q13 segmental paternal UPD in 55% of the cells. Except for the possibility of homozygosity for recessive mutations, maternal UPD 22 does not seem to have an adverse impact on the phenotype. 20 This means that no maternally imprinted gene with major effect maps to chromosome 22. The phenotypic effects of paternal UPD 22 are still unknown, as no cases have been reported. Accordingly, our proband's clinical phenotype may or may not depend entirely on the presence and level of the mosaic 22q13 deletion. Psychomotor delay was more severe in Case 2 (73% of deleted cells in blood and over 80% in saliva) than in Case 1 (45% deleted cells in both blood and saliva). Similarly in the case reported by Yong, 18 with 95% of deleted cells, psychomotor delay was severe (Table 1) . Whatever the level of mosaicism in the brain may be, it is enough to express the full neurological phenotype of the syndrome. Haploinsufficiency of the SHANK3 gene is the main cause of the neurological phenotype in the 22q13 deletion syndrome. 7 -10 Our cases demonstrate that even in mosaicism haploinsufficiency of SHANK3 is sufficient to severely perturb its activity. Segmental isodisomy is usually assumed to be produced postzygotically by a mitotic exchange between non-sister chromatids. However, both maternal and paternal UPD should than be found in daughter cells, unless the mitotic event occurs very early and the products split between embryonic and extraembryonic tissues, or one of the products is lethal, as assumed in Beckwith -Wiedemann syndrome. 21 In our case, deletion and segmental UPD break points, while very close, do not coincide: on the UPD 22 chromosome, SNPs 1226 -1246 and rs10483213, all distal to the deletion break point, contain a maternal allele ( Figure 2a and Table 2 ). Fish analysis also demonstrated the presence of a cell with three copies of non-deleted chromosome 22. On the basis of these findings, we hypothesize two possible mechanisms leading to the formation of this complex mosaic. In the first model (Figure 3a) , a meiotic or post-meiotic event generated a deletion on the maternally inherited chromosome 22. During replication, one deleted chromatid repaired itself through break-induced replication 22, 23 using one of the paternal chromatids as a template, generating a gene conversion during the process. This event resulted in the 55% Pat UPD þ gene conversion lineage. The remaining replicated deleted maternal allele, still containing an unprotected chromosome end, lost several kilobases because of exonucleolytic activity. The secondary structure produced by the AT-rich repeat probably protected the chromosome from further degradation and facilitated stabilization by telomere healing. This is why the deletion break point of the maternal deleted chromosome 22 is located in the middle of a 1.3 kb AT-rich repeat. In the second model (Figure 3b ), based on FISH data showing the presence of one cell with three copies of nondeleted chromosome 22, the rearrangement occurred in a trisomic zygote with two paternal 22q and one maternal 22q chromosomes. A multiple recombination event involving all three chromosomes caused gene conversion, segmental UPD, and deletion; the deleted chromosome then lost several kilobases before being stabilized by the addition of telomeric sequences.
Mechanisms of mosaicism
In Case 2, the presence of a normal cell line is, most likely, consistent with a postzygotic event, requiring a single hit to explain both the deletion and the mosaicism (Supplementary Figure 4) . A break during DNA replication in the zygote would generate a deleted chromatid, immediately stabilized by telomere healing. Segregation gave rise to a cell line with normal karyotype and another with 22q13 deletion.
In conclusion, we have described two patients with mosaic (45 -75%) terminal 22q13 deletions, one of whom additionally carries a mosaic 22q13 segmental UPD (Case 1).
Keeping in mind that both cases showed the same 22q13 deletion size:
(1) the clinical phenotype, much more severe in case 2 than in case 1, should depend entirely on the presence of the mosaic 22q13 deletion; mosaic segmental UPD22 probably does not have relevant clinical impact. (2) the complex mosaicism in Case 1 originated from a postzygotic or early embryonic recombination event causing a gene conversion event leading to the formation of segmental UPD and terminal deletion, both retained in mosaic in the fetus. Mosaicism in Case 2 was also probably due to a postzygotic event.
